Childhood nephrotic syndrome--current and future therapies.
about
Corticosteroid therapy for nephrotic syndrome in childrenSetting New Directions for Research in Childhood Nephrotic Syndrome: Results From a National WorkshopThe primary glomerulonephritides: a systems biology approach.Defining nephrotic syndrome from an integrative genomics perspective.Albumin-induced podocyte injury and protection are associated with regulation of COX-2.Huaier Cream Protects against Adriamycin-Induced Nephropathy by Restoring Mitochondrial Function via PGC-1α UpregulationSteroid-sensitive nephrotic syndrome in children: triggers of relapse and evolving hypotheses on pathogenesis.Calpain-Mediated Cleavage of Calcineurin in Puromycin Aminonucleoside-Induced Podocyte Injury.Dexamethasone-dependent modulation of cyclic GMP synthesis in podocytes.Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway.Leveraging melanocortin pathways to treat glomerular diseases.Control of inflammatory heart disease by CD4+ T cells.An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.Markers of disease and steroid responsiveness in paediatric idiopathic nephrotic syndrome: Whole-transcriptome sequencing of peripheral blood mononuclear cells.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence.Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome.Ethnic Differences in Incidence and Outcomes of Childhood Nephrotic Syndrome.Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1Association of long-term tacrolimus (FK506) therapy with abnormal megakaryocytosis, bone marrow fibrosis, and dyserythropoiesis.50 years of nephrotic syndrome in children, and hereafter.Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.Paediatric nephrology: the last 50 years.Vitamin D in nephrotic syndrome remission: a case-control study.Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome.Inhibition of Rho-associated kinase relieves C5a-induced proteinuria in murine nephrotic syndrome.Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments.
P2860
Q24187231-EC3388FF-A5F3-400D-B529-AD0B342D1EB1Q33605545-995E57F1-EBA2-43D1-9BFA-2944A8DB5024Q34462626-175D2064-F35B-49EA-A3F3-6BC15CE35B02Q34560989-27B6F437-FD31-49FD-957C-022F9BD329CCQ34577309-CA7D1B85-964E-4554-B712-6180E41EDD8DQ35226985-D88C1524-996B-42D1-B7B4-78B2E6907B7DQ35233125-D9B9D5DE-E8D5-4666-BE1E-1E7AD185BBADQ36015453-649F89A8-4F1A-4E40-BF4E-38032A502DB8Q36109237-0FB312D8-0A7F-4248-8776-FF127C6F9AEAQ36864663-56E2F0F2-80CE-4B34-8474-97CB1F19D7A4Q36980645-A41A3CE7-DD96-41E7-8DBD-824320CB4779Q37555498-4FA0D0AD-3C96-4D81-93CF-85910BB72C43Q37632054-F904C83C-B498-4B1A-90D0-37624107155CQ38108397-488E06CC-CE6E-4666-83E5-86A6C901FA91Q38232593-955EDC3F-5FF6-45E0-9D8D-57F494AD72F7Q38667777-82551D13-2ECE-49D9-B402-F3A8D3B1F9F1Q38714386-AE01B0C2-ADA6-4CFA-8417-099C9F12F27EQ38738516-E3DE8970-DE32-4D87-9802-0E5821842122Q38829694-6D40AE30-8E37-4FB4-A007-826D975CB137Q38895019-E6654871-6C48-46F4-9EB8-72433DF11B8DQ39374379-94750F82-3AB7-41B0-9383-EE66EBD782ECQ39398182-D5271FFA-38DC-4E4D-BAE3-A4292DDA8A0AQ39573377-7F9A4D3B-E720-4500-B46D-B7AC95B09587Q41159058-5831DB4C-797D-4AF0-82EC-401551958193Q42147158-30B55E74-64B5-4A3A-9692-952BB6EA5937Q44201628-8EA8EB4B-F0F2-4637-A78D-EC65E415E4B2Q47363893-F8607B7A-A96E-4A8C-BF3C-C2CE5557F4C7Q48055250-8C7D3FCC-4FC4-4D45-AAB8-92043CA48E6BQ50959482-D99FAE07-EB1E-4EE0-AAF8-B3252AE413E5Q51226993-67A171CA-4997-4D3B-A8CA-B42A95FE9B5AQ53960749-9EFDD5F0-761B-45C9-866A-32E6C0D85D6CQ55005671-3512A5AF-9198-4986-B3FF-4AF86F08F659
P2860
Childhood nephrotic syndrome--current and future therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Childhood nephrotic syndrome--current and future therapies.
@en
type
label
Childhood nephrotic syndrome--current and future therapies.
@en
prefLabel
Childhood nephrotic syndrome--current and future therapies.
@en
P2093
P2860
P356
P1476
Childhood nephrotic syndrome--current and future therapies.
@en
P2093
Larry A Greenbaum
Rainer Benndorf
William E Smoyer
P2860
P2888
P304
P356
10.1038/NRNEPH.2012.115
P407
P577
2012-06-12T00:00:00Z
P6179
1018704609